NOX 0.00% 12.0¢ noxopharm limited

Ann: mRNA Vaccine Enhancer Shows Inflammation Reduction, page-46

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 6 Posts.
    lightbulb Created with Sketch. 8
    The rationale was explained at the AGM. mRNA vaccines or drugs induce inflammation courtesy of the TLR-7 receptor. Moderna and Pfizer/BioNTech have exclusive licence to the technology invented by the two recent Nobel Prize winners to help block the inflammatory response. All other companies interested in mRNA vaccines or drugs have been locked out of that technology and need to find another way to allow them onto the market. NOX believes that it has the only other way. So, I take it from that explanation that prospective Licensees are everyone else apart from Moderna and Pfizer/BioNTech.
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
12.0¢
Change
0.000(0.00%)
Mkt cap ! $35.06M
Open High Low Value Volume
12.0¢ 12.0¢ 11.5¢ $5.653K 48.83K

Buyers (Bids)

No. Vol. Price($)
3 22101 11.5¢
 

Sellers (Offers)

Price($) Vol. No.
12.0¢ 159073 5
View Market Depth
Last trade - 16.10pm 18/10/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.